CN104523700A - Application of hederagenin to preparation of drug for resisting to MGC-803 tumors of gastric cancer - Google Patents
Application of hederagenin to preparation of drug for resisting to MGC-803 tumors of gastric cancer Download PDFInfo
- Publication number
- CN104523700A CN104523700A CN201410787875.0A CN201410787875A CN104523700A CN 104523700 A CN104523700 A CN 104523700A CN 201410787875 A CN201410787875 A CN 201410787875A CN 104523700 A CN104523700 A CN 104523700A
- Authority
- CN
- China
- Prior art keywords
- helexin
- tumor
- hederagenin
- dosage
- nude mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of hederagenin to preparation of an antitumor drug. The hederagenin disclosed by the invention is extracted from radix dipsaci serving as a natural medicinal material, and the radix dipsaci is a common traditional Chinese medicine material, has long-term traditional Chinese medicine application experience and is high in using safety and free of remarkable toxic effect records. Researches show that the hederagenin is exact in antitumor activity and remarkable in effect and has higher safety performance and fewer side effects than an antitumor western medicine so as to be expected to be developed into an antitumor drug.
Description
The application is the applying date is on 09 28th, 2013, and application number is 2013104529876, and denomination of invention is that helexin is in the divisional application preparing the application in antitumor drug.
Technical field:
The invention belongs to the field of Chinese medicines, be specifically related to helexin and preparing the application in antitumor drug.
Technical background:
Tumor is the maximum killer one of human health.Effect of Anti tumour medicine worldwide becomes focus.Synthetic drug at antineoplastic simultaneously, produces huge injury to human body.From natural drug, research and the discovery effectively compound of low toxicity, significant.
Helexin (Hederagenin), another name (3beta, 4alpha)-3,23-Dihydroxyolean-12-en-28-oicacid; Hederagenin, molecular formula C
30h
48o
4, structural formula is:
Summary of the invention:
Helexin is the object of the present invention is to provide to prepare the application in antitumor drug.
Object of the present invention is achieved through the following technical solutions:
Helexin is preparing the application in antitumor drug.
Above-mentioned application, it is that described helexin has at body anti-tumor activity, and described at body anti-tumor activity is: anti-breast cancer MCF-7 tumor, suppressing lung cancer A 549 tumor, anti-hepatocarcinoma Hep3B tumor, anti-Gastric Cancer MGC-803 tumor, inhibitor against colon carcinoma cells LoVo tumor, ovarian cancer resistance HO-8910PM tumor, anti-endometrial carcinoma cell HEC-1 tumor, resisting leukemia K 562 tumor, anti-esophageal squamous cell carcinoma cell Eca-109 tumor.
Above-mentioned application, it is that the purity of described helexin is 50% ~ 99%.
Above-mentioned application, it is that described antitumor drug comprises helexin and pharmaceutically acceptable carrier or conventional edible adjuvant.
The dosage form of above-mentioned antitumor drug is any one dosage form pharmaceutically acceptable.
Helexin of the present invention extracts and obtains from crude drug Radix Dipsaci, and Radix Dipsaci is conventional Chinese crude drug, take Radix Dipsaci as the method that different purity helexin prepared by raw material is known in those skilled in the art.
Room temperature of the present invention is 25 ± 5 DEG C known in those skilled in the art.
Beneficial effect of the present invention:
Helexin of the present invention extracts and obtains from crude drug Radix Dipsaci, and Radix Dipsaci is conventional Chinese crude drug, and have long-term traditional Chinese medical science medication experience, this medicine is safe to use, and free of toxic effects is recorded.
Research shows, helexin has definite anti-tumor activity, Be very effective, comparatively safe compared with Western medicine antitumor, and side effect is little, has the prospect being developed to antitumor drug.
Detailed description of the invention:
Embodiment 1: the preparation of trial drug helexin:
Helexin (self-control, purity is 50%, 99%, preparation method: get Radix Dipsaci medical material, suitable pulverizing, ethanol extraction with 90% 3 times, filter, merge 3 filtrates, decompression recycling ethanol is extremely without alcohol taste, ethanol with 50% is settled to 1g medical material/30mL, the hydrochloric acid adding liquor capacity mark 7% ~ 10% is (commercially available, analytical pure, mass fraction is 37%), water-bath refluxes 3 hours, hydrolysis temperature (bath temperature) is 80 DEG C, hydrolyzed solution decompression recycling ethanol is extremely without alcohol taste, place 24 ~ 36 hours at ambient temperature, precipitation, filter, obtain precipitate, less than 65 DEG C drying under reduced pressure, obtaining purity is 50% helexin precipitate, through repeatedly washing on a small quantity, wash through the ethanol of a small amount of 5%, less than 65 DEG C drying under reduced pressure, obtaining purity is 99% helexin).
Embodiment 2:
Helexin anti-human breast cancer in nude mice MCF-7 tumor, anti-lung cancer in nude mice A549 tumor, anti-hepatocellular carcinoma in nude mice Hep3B tumor, anti-gastric cancer in nude mice MGC-803 tumor, anti-nude mice colon cancer LoVo tumor, anti-ovarian Cancer of Nude Mice HO-8910PM tumor, anti-nude mice endometrial carcinoma cell HEC-1 tumor, anti-nude mice leukemia K 562 tumor, anti-nude mice esophageal squamous cell carcinoma cell Eca-109 tumor experiment:
1. breast carcinoma MCF-7 nude mice is at body anti-tumor experiment
1.1 experimental techniques:
To take the logarithm the MCF-7 Human Breast Cancer Cells strain of trophophase, be aseptically prepared into 1 × 10 afterwards
8/ ml cell suspension, on the right side of being inoculated in BALB/c nude mouse with 0.1ml, axillary fossa is subcutaneous.Nude Mice vernier caliper measurement transplanted tumor diameter, treats tumor growth to 100 ~ 300mm
3after by animal random packet.Use the method measuring tumor footpath, dynamically observe tested thing antineoplastic effect.The pendulous frequency of diameter of tumor is survey 1 time for every 4 days.Administration volume is 0.4ml/20g.Every day is administered once, altogether administration 28 days.Negative control group gavages and gives isopyknic normal saline, and tamoxifen dosage is 4mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.After 29 days, put to death mice, operation strips tumor block and weighs.
1.2 positive drug:
Tamoxifen (producer: Yangzijiang Pharmaceutical Group Co., Ltd, lot number: 12070411, specification: 10mg/ sheet × 60 slice).Compound method: each administration, the thing tamoxifen sheet 10mg that gets it filled adds CMC-Na 50ml, and be mixed with the liquid that concentration is 0.2mg/ml, administration volume is 0.4ml/20g, and namely dosage is 4mg/kg.
Tweight: the average tumor weight of administration group; Cweight: the average tumor weight of negative control group.
1.3 experimental result
The inhibitory action that table 1. helexin grows human breast carcinoma MCF-7 nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.60±0.14 | — |
| Tamoxifen | 4 | 0.16±0.11** | 73.33％ |
| 99% helexin high dose group | 405 | 0.21±0.05** | 65.00％ |
| Dosage group in 99% helexin | 135 | 0.22±0.06** | 63.33％ |
| 99% helexin low dose group | 45 | 0.23±0.05** | 61.67％ |
| 50% Hederagenin tuple | 270 | 0.24±0.08** | 60.00％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
2. pulmonary carcinoma A549 nude mice is at body anti-tumor experiment
2.1 experimental techniques:
SPF level BALB/c nude mice 60,6 week age, weight 16 ~ 18g.Take the logarithm trophophase A549 cell, adjusting A549 cell concentration with aseptic PBS is 3 × 10
7/ mL, at BALB/c nude mice dorsal sc inoculation A549 cell 0.1mL, treats that subcutaneous transplantation tumor volume reaches 75mm
3during left and right (about 10d), by tumor volume and the grouping of mice with tumor body weight homeostatic principle.Daily 1 time, administration 28 days, during administration every 4 days with the most major diameter (L) of vernier caliper measurement transplanted tumor and most minor axis (W).After last administration 48h, mice is put to death in dislocation, and excision transplanted tumor, takes tumor weight.Negative control group lumbar injection equal-volume normal saline, cisplatin (DDP) dosage is 2mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, and the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.
2.2 positive drug:
Cisplatin (DDP) (Qilu Pharmaceutical Co., Ltd., batch number: 509017IDB, specification: often prop up 10mg).Dosage is 2.0mg/kg, i.p.
The inhibitory action that table 2. helexin grows pulmonary carcinoma A549 nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.69±0.10 | — |
| Cisplatin | 2 | 0.13±0.09** | 81.16％ |
| 99% helexin high dose group | 405 | 0.21±0.07** | 69.56％ |
| Dosage group in 99% helexin | 135 | 0.22±0.04** | 68.12％ |
| 99% helexin low dose group | 45 | 0.23±0.06** | 66.67％ |
| 50% Hederagenin tuple | 270 | 0.25±0.010** | 63.77％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
3. hepatocarcinoma Hep3B nude mice is at body anti-tumor experiment
3.1 experimental techniques:
The Hep3B cell strain of exponential phase is mixed with normal saline, makes single cell suspension, by every 1 × 10
7individual cell injects outside the right rear leg of nude mice back subcutaneous, totally 60.After 4 days, there is the hard lump of tangibly matter.Treat that growth of xenografted is to about 0.3cm
2, be divided into 6 groups at random, often organize 10.Daily 1 time, administration 28 days altogether.During administration every 4 days with the most major diameter (L) of vernier caliper measurement transplanted tumor and most minor axis (W).After last administration 48h, mice is put to death in dislocation, and excision transplanted tumor, takes tumor weight.Negative control group lumbar injection equal-volume normal saline, Fluorouracil Injection (5-FU injection) dosage is 20mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, and the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.
3.2 positive drug:
Fluorouracil Injection (5-FU injection) (Tianjin Jin Yao aminoacid company limited product, lot number 1311171).5-FU matched group dosage is 20mg/kg, i.p.
The inhibitory action that table 3. helexin grows hepatocarcinoma Hep3B nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.61±0.04 | — |
| Fluorouracil | 20 | 0.17±0.04** | 72.13％ |
| 99% helexin high dose group | 405 | 0.21±0.05** | 65.57％ |
| Dosage group in 99% helexin | 135 | 0.22±0.03** | 63.93％ |
| 99% helexin low dose group | 45 | 0.23±0.06** | 62.30％ |
| 50% Hederagenin tuple | 270 | 0.24±0.07** | 60.66％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
4. Gastric Cancer MGC-803 nude mice is at body anti-tumor experiment
4.1 experimental techniques:
Prepare cell suspension, low differentiation Patients with Mucinous Gastric Carcinoma MGC-803 cell strain cell concentration to 300 ten thousand of giving sb. a hard time lowered by mirror, cell suspension 0.3mL (about 1,000,000 cells) is injected nude mice nape subcutaneous, aseptic nursing 4 weeks, be prepared into tumor source nude mice and put to death tumor source nude mice, take out transplanted tumor and shred into 2mm
3the tumor block of size, is seeded to each experimental mouse aseptic nursing 1week and is prepared into tumor bearing nude mice.Negative control group lumbar injection equal-volume normal saline, Fluorouracil Injection (5-FU injection) dosage is 20mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, the low dosage of 50% helexin is 45mg/kg, and 50% helexin is 270mg/kg.Daily 1 time, administration 28 days altogether.
4.2 positive drug:
Fluorouracil Injection (5-FU injection) (Tianjin Jin Yao aminoacid company limited product, lot number 1311171).
The inhibitory action that table 4. helexin grows Gastric Cancer MGC-803 nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.58±0.08 | — |
| Fluorouracil | 50 | 0.15±0.06** | 74.14％ |
| 99% helexin high dose group | 405 | 0.17±0.04** | 70.69％ |
| Dosage group in 99% helexin | 135 | 0.18±0.05** | 68.97％ |
| 99% helexin low dose group | 45 | 0.20±0.03** | 65.52％ |
| 50% Hederagenin tuple | 270 | 0.22±0.10** | 62.07％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
5. colon cancer LoVo nude mice is at body anti-tumor experiment
5.1 test method
BALB/C nude mice 60, purchased from Chinese Academy of Medical Sciences's Shanghai Experimental Animal Center, 4 ~ 6 weeks ages of Mus, body weight 20 ~ 25g, nude mice indoor feeding under SPF condition.Aseptically, nude mouse right fore dorsal sc injection LoVo cell, there is obvious skin mound in injection site, allly after 7d is vaccinated nude mouse and all occurs tuberosity, and Nude Mouse Model is set up, and is then divided into 6 groups at random, often organizes 10.Negative control group lumbar injection equal-volume normal saline, Fluorouracil Injection (5-FU injection) lumbar injection dosage is 20mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, and the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.Daily 1 time, continuous 28d.
5.2 positive drug
5%5-FU injection (Tianjin Jin Yao aminoacid company limited product, lot number 1311171).
The inhibitory action that table 5. helexin grows colon cancer LoVo nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.59±0.07 | — |
| Fluorouracil | 20 | 0.16±0.09** | 72.88％ |
| 99% helexin high dose group | 405 | 0.18±0.03** | 69.49％ |
| Dosage group in 99% helexin | 135 | 0.20±0.06** | 66.10％ |
| 99% helexin low dose group | 45 | 0.22±0.05** | 62.71％ |
| 50% Hederagenin tuple | 270 | 0.21±0.09** | 64.41％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
6. ovarian cancer HO-8910PM nude mice is at body anti-tumor experiment
6.1 experimental techniques:
Select female BAl BIc/c nude mice in 4 ~ 6 week age, by 2 × 10
7individual HO-8910PM cell suspension is in 0.2mL serum-free RPMI-1640 culture medium, and be expelled to nude mice back near right hindlimb is subcutaneous and set up ovarian Cancer of Nude Mice subcutaneous transplantation tumor model, postoperative nude mice continues to raise in SPF laboratory.After inoculating 2 weeks, treat that transplanted tumor volume grows to 100 ~ 150mm
3tumor bearing nude mice is divided into 6 groups at random, often organize 10, negative control group gavage only gives distilled water 0.2mL/, Docetaxel dosage is 0.5mg/kg, the high dose of 99% helexin is 405mg/kg, and the middle dosage of 99% helexin is 135mg/kg, and the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.
Daily 1 time, administration 28 days altogether.Within 8th week, put to death nude mice, get subcutaneous transplantation tumor tissue, measure tumor quality; Tumour inhibiting rate=(the average tumor weight of 1-administration group average tumor weight/negative control group) × 100%.
6.2 positive drug:
Docetaxel group (0.5mg/kg) (permanent auspicious medicine).
The inhibitory action that table 6. helexin grows ovarian cancer HO-8910PM nude mouse xenograft tumor
note: compare with negative control group, * P<0.05, * * P<0.01.
7. endometrial carcinoma cell HEC-1 nude mice is at body anti-tumor experiment
7.1 experimental techniques:
With 75% ethanol disinfection nude mice bilateral back part skin on superclean bench, extract the good concentration (1 × 10 of adjusted with 1ml empty needle
8ml
-1) endometrial carcinoma cell suspension, every side subcutaneous vaccination 0.2ml is (containing cell number 2 × 10
7individual).Whether modeling is evaluated in modeling on the 10th day successful.60 nude mices are divided into 6 groups after setting up by model at random, often organize 10.Respectively at modeling administration in the 11st day, negative control group respectively gavage only gives distilled water 0.2mL/, and cisplatin dose is 3mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.Daily 1 time, successive administration 4 weeks.
7.2 positive drug and carcinoma of endometrium HEC-I cell:
Carcinoma of endometrium HEC-I cell is purchased from Chinese Academy of Sciences's cell bank, and cisplatin is purchased from Sigma.
The inhibitory action that table 7. helexin grows endometrial carcinoma cell HEC-1 nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.62±0.07 | — |
| Cisplatin | 3 | 0.15±0.06** | 75.81％ |
| 99% helexin high dose group | 405 | 0.18±0.07** | 70.97％ |
| Dosage group in 99% helexin | 135 | 0.22±0.03** | 64.52％ |
| 99% helexin low dose group | 45 | 0.25±0.05** | 59.68％ |
| 50% Hederagenin tuple | 270 | 0.24±0.11** | 61.29％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
8. leukemia K 562 nude mice is at body anti-tumor experiment
8.1 experimental techniques:
To take the logarithm in biological clean bench the K562 cell strain of trophophase, be not mixed with 1 × 10 by the RPMI1640 culture medium containing serum
12individual/L single cell suspension.The aseptic 1ml syringe subcutaneous vaccination 0.1ml cell suspension in axillary fossa place on the right side of 60 nude mices, and be designated as inoculation the 1st day.Inoculation the 12nd day, most of nude mice was tangible to Subcutaneous tumor.Filter out gross tumor volume and be about 100mm
360 tumor bearing nude mices, be divided into negative control group (water is steamed in sterilizing two, 10ml/kg), positive controls, the high, medium and low dosage group of 99% helexin and 50% Hederagenin tuple by randomization, totally 6 groups, often organize 10.The 2nd day after grouping starts administration.CTX group gives through lumbar injection the aseptic CTX normal saline solution that concentration is 2.5mg/ml, every 2 days 1 time; Negative control group, 99% helexin each dosage group, the equal gastric infusion of 50% Hederagenin tuple, every day 1 time, altogether 28d.Each group all by every nude mice 10ml/kg administration.Cyclophosphamide (CTX) dosage is 25mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.
8.2 positive drug:
Cyclophosphamide for injection (CTX, lot number 10052341, Hengrui Medicine Co., Ltd., Jiangsu Prov.).
The inhibitory action that table 8. helexin grows leukemia K 562 nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.64±0.10 | — |
| Cyclophosphamide | 25 | 0.15±0.08** | 76.56％ |
| 99% helexin high dose group | 405 | 0.18±0.09** | 71.88％ |
| Dosage group in 99% helexin | 135 | 0.20±0.07** | 68.75％ |
| 99% helexin low dose group | 45 | 0.24±0.08** | 62.50％ |
| 50% Hederagenin tuple | 270 | 0.23±0.11** | 64.06％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
9. esophageal squamous cell carcinoma cell Eca-109 nude mice is at body anti-tumor experiment
9.1 experimental techniques:
Every Mus dorsal sc injection is about 0.2mL aseptic esophageal squamous cell carcinoma cell Eca-109 cell suspension (containing 6.0 × 10
6~ 8.0 × 10
6cell), after inoculation every two days with the most major diameter a of vernier caliper measurement tumor body and most minor axis b, calculate gross tumor volume V=1/2ab
2, after 1 week, treat that gross tumor volume grows to about 0.2cm
3rear random packet, often organizes 10.Negative control group lumbar injection equal-volume normal saline, Fluorouracil Injection (5-FU injection) lumbar injection dosage is 10mg/kg, the high dose of 99% helexin is 405mg/kg, the middle dosage of 99% helexin is 135mg/kg, and the low dosage of 99% helexin is 45mg/kg, 50% helexin is 270mg/kg.Be daily 1 time, continuous 28d.
9.2 positive drug:
5-Fu (10mL/0.25g) (Tianjin Jin Yao aminoacid company limited product, lot number 1311171), 5-Fu presses 10mg/kg lumbar injection.
The inhibitory action that table 9. helexin grows esophageal squamous cell carcinoma cell Eca-109 nude mouse xenograft tumor
| Group | Dosage (mg/kg) | Tumor heavy (g) | Tumour inhibiting rate (%) |
| Negative control group | — | 0.63±0.12 | — |
| Fluorouracil | 10 | 0.17±0.07** | 73.02％ |
| 99% helexin high dose group | 405 | 0.19±0.05** | 69.84％ |
| Dosage group in 99% helexin | 135 | 0.21±0.06** | 66.67％ |
| 99% helexin low dose group | 45 | 0.24±0.04** | 61.90％ |
| 50% Hederagenin tuple | 270 | 0.23±0.09** | 63.49％ |
Note: compare with negative control group, * P<0.05, * * P<0.01.
Conclusion:
Helexin has at body anti-tumor activity.At body anti-tumor activity be specifically: anti-human breast cancer in nude mice MCF-7 tumor, anti-lung cancer in nude mice A549 tumor, anti-hepatocellular carcinoma in nude mice Hep3B tumor, anti-gastric cancer in nude mice MGC-803 tumor, anti-nude mice colon cancer LoVo tumor, anti-ovarian Cancer of Nude Mice HO-8910PM tumor, anti-nude mice endometrial carcinoma cell HEC-1 tumor, anti-nude mice leukemia K 562 tumor, anti-nude mice esophageal squamous cell carcinoma cell Eca-109 tumor.
Embodiment 3: purity is 99% helexin, purity is 50% helexin sample formulation
The preparation method of 98% Hederagenin Yuan capsule: 99% helexin powder in Example 1, adds 1% ~ 15% starch or other pharmaceutically acceptable carrier or conventional edible adjuvant (or other pharmaceutically acceptable carrier or conventional edible adjuvant: pharmaceutically acceptable carrier comprises the adjuvant of oral formulations adjuvant or Parenteral.Route of administration can be oral, injection, topical etc.According to technical scheme of the present invention, said composition can be oral formulations or injection preparation, and wherein oral formulations comprises capsule, soft capsule, granule, oral liquid, tablet, drop pill etc.Adjuvant used comprises: starch, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, Polyethylene Glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol, microcrystalline Cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, cysteine, citric acid, sodium thiosulfate, sodium sulfite, the customary adjuvant such as stearate and gelatin, preparation later stage preparation technology and equipment all belong to the routine techniques of pharmaceutical field, the present invention is not construed as limiting this, therefore will not describe in detail at this), with 90% ethanol (or the ethanol of other concentration, water) be wetting agent, prepare soft material, cross 20 mesh sieves to granulate, dry at 60 DEG C, 20 mesh sieves arrange, obtain conforming particle, fill No. 0 capsule, for 0.315g/ grain weight, wherein 0.015g/ adjuvant grain, 99% helexin/the grain of 0.300g.Day takes 3 times, each 1-3 grain.
The preparation method of 50% Hederagenin Yuan capsule: 50% helexin powder in Example 1, add 1% ~ 15% starch or other pharmaceutically acceptable carrier or conventional edible adjuvant, be wetting agent with 90% ethanol (or the ethanol of other concentration, water), prepare soft material, cross 20 mesh sieves to granulate, dry at 60 DEG C, 20 mesh sieves arrange, obtain conforming particle, fill No. 0 capsule, for 0.315g/ grain weight, wherein 0.015g/ adjuvant grain, the 50% helexin/grain of 0.300g.Day takes 3 times, each 2-4 grain.
Claims (3)
1. the application of helexin in anti-Gastric Cancer MGC-803 tumour medicine of preparation.
2. application according to claim 1, is characterized in that the purity of described helexin is 50% ~ 99%.
3. application according to claim 1, is characterized in that described antitumor drug comprises helexin and pharmaceutically acceptable carrier or conventional edible adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410787875.0A CN104523700A (en) | 2013-09-28 | 2013-09-28 | Application of hederagenin to preparation of drug for resisting to MGC-803 tumors of gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410787875.0A CN104523700A (en) | 2013-09-28 | 2013-09-28 | Application of hederagenin to preparation of drug for resisting to MGC-803 tumors of gastric cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310452987.6A Division CN103463098B (en) | 2013-09-28 | 2013-09-28 | Application of hederagenin for preparing antineoplastic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104523700A true CN104523700A (en) | 2015-04-22 |
Family
ID=52839459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410787875.0A Pending CN104523700A (en) | 2013-09-28 | 2013-09-28 | Application of hederagenin to preparation of drug for resisting to MGC-803 tumors of gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104523700A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406509A (en) * | 2008-11-28 | 2009-04-15 | 江苏省中国科学院植物研究所 | Lonicera confusa extract and preparation method and application thereof |
| CN102178688A (en) * | 2011-04-07 | 2011-09-14 | 江西本草天工科技有限责任公司 | Preparation method of ivy saponins ingredient and application of the ingredient to resisting tumors |
| CN102702299A (en) * | 2012-06-19 | 2012-10-03 | 杨中林 | Preparation method of hederagenin |
| CN103830293A (en) * | 2012-11-21 | 2014-06-04 | 青岛百草汇中草药研究所 | Medicine with hederagenin as active ingredient, and applications of medicine in medicine preparation |
-
2013
- 2013-09-28 CN CN201410787875.0A patent/CN104523700A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406509A (en) * | 2008-11-28 | 2009-04-15 | 江苏省中国科学院植物研究所 | Lonicera confusa extract and preparation method and application thereof |
| CN102178688A (en) * | 2011-04-07 | 2011-09-14 | 江西本草天工科技有限责任公司 | Preparation method of ivy saponins ingredient and application of the ingredient to resisting tumors |
| CN102702299A (en) * | 2012-06-19 | 2012-10-03 | 杨中林 | Preparation method of hederagenin |
| CN103830293A (en) * | 2012-11-21 | 2014-06-04 | 青岛百草汇中草药研究所 | Medicine with hederagenin as active ingredient, and applications of medicine in medicine preparation |
Non-Patent Citations (2)
| Title |
|---|
| HEE-JUHN PARK 等: "Kalopanaxsaponin A is a Basic Saponin Structure for the Anti-Tumor Activity of Hederagenin Monodesmosides", 《PLANTA MED》 * |
| 刘包欣子等: "常春藤皂苷元对胃癌细胞MGC-803增殖、黏附、侵袭和迁移能力的影响", 《中国实验方剂学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN103463098B (en) | Application of hederagenin for preparing antineoplastic drugs | |
| CN102475698B (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN101926844B (en) | Stellera chamaejasme L extract and anti-tumor action thereof | |
| CN101773499A (en) | New applications of tetrahydropalmatine | |
| CN101229175A (en) | Medical applications of couple protopanoxadiol derivatives and compound body thereof | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN104523698A (en) | Application of hederagenin to preparation of drug for resisting to HEC-1 tumors of endometrial carcinoma cells | |
| CN102716320A (en) | Medicinal composition for treating non-small cell lung cancer | |
| CN104189782A (en) | Anti-tumor medicament composition | |
| CN102370645A (en) | Anticancer drug composition | |
| CN104523700A (en) | Application of hederagenin to preparation of drug for resisting to MGC-803 tumors of gastric cancer | |
| CN104523699A (en) | Application of hederagenin to preparation of drug for resisting to HO-8910PM tumors of ovarian cancer | |
| CN104546866A (en) | Application of hederagenin in preparation of medicine for resisting tumors of esophageal squamous carcinoma cell Eca-109 | |
| CN104546865A (en) | Application of hederagenin in preparation of medicine for resisting liver cancer leukemia K562 tumors | |
| CN104546864A (en) | Application of hederagenin in preparation of medicine for resisting liver cancer Hep3B tumors | |
| CN104337823A (en) | Pharmaceutical composition for restraining tumors | |
| CN103655559A (en) | Application of incarvillateine compounds in preparation of anti-breast cancer drugs | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| CN102309493B (en) | Anti-cancer medicinal composition | |
| CN103830262A (en) | Auxiliary drug used for treating cancer, and applications thereof | |
| CN111388665B (en) | Compound for treating tumor and preparation and application thereof | |
| CN101269110B (en) | Radix astragali fermentation liquor for inhibiting cancer cell growth and fermentation method | |
| CN110755594B (en) | Application of double-ginger stomachache prescription in preparation of medicine for treating inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |